CAPR Stock Price, Capricor Therapeutics Quote, Chart

Market Summary

USD6.24+0.60

Delayedas of 17 May 2024, 03:02 pm

10.64%

CAPR Stock Price

View Fullscreen

CAPR RSI Chart

CAPR Valuation

Market Cap

179.4M

Price/Earnings (Trailing)

-7.38

Price/Sales (Trailing)

6.62

Price/Free Cashflow

-5.5

CAPR Price/Sales (Trailing)

CAPR Profitability

Return on Equity

-131.89%

Return on Assets

-49.17%

Free Cashflow Yield

-18.2%

CAPR Fundamentals

CAPR Revenue

Revenue (TTM)

27.1M

Rev. Growth (Yr)

64.29%

Rev. Growth (Qtr)

-59.41%

CAPR Earnings

Earnings (TTM)

-24.3M

Earnings Growth (Yr)

-26.08%

Earnings Growth (Qtr)

-1.2K%

Breaking Down CAPR Revenue

52 Week Range

2.758.22

(Low)(High)

Last 7 days

3.7%

Last 30 days

-5.2%

Last 90 days

55.7%

Trailing 12 Months

29.3%

How does CAPR drawdown profile look like?

CAPR Financial Health

Current Ratio

1.57

CAPR Investor Care

Shares Dilution (1Y)

25.89%

Diluted EPS (TTM)

-0.83

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	27.1M	0	0	0
2023	5.5M	9.5M	14.0M	25.2M
2022	0	0	1.8M	2.6M
2021	165.4K	319.6K	302.7K	244.9K
2020	960.2K	599.7K	474.5K	310.3K
2019	1.5M	1.5M	1.4M	1.0M
2018	2.2M	1.6M	1.5M	1.7M
2017	3.7M	3.5M	3.1M	2.7M
2016	4.9M	4.8M	4.2M	4.0M
2015	5.5M	5.8M	5.8M	5.5M
2014	1.3M	2.2M	3.4M	4.8M
2013	1.9M	2.1M	2.2M	503.2K
2012	1.5M	1.6M	1.8M	1.9M
2011	0	0	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Capricor Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 23, 2024	collier earl m jr	acquired	41,700	1.39	30,000	-
Apr 23, 2024	musket david b	acquired	22,456	1.39	16,156	-
Oct 23, 2023	bergmann anthony	acquired	3,027	1.39	2,178	chief financial officer
Oct 12, 2023	musket david b	bought	1,127	2.75	410	-
Oct 10, 2023	collier earl m jr	bought	28,300	2.83	10,000	-
Oct 09, 2023	musket david b	bought	14,334	2.82	5,083	-
Oct 06, 2023	auwaerter paul gisbert	bought	14,200	2.84	5,000	-
Oct 04, 2023	musket david b	bought	7,250	2.9	2,500	-
Aug 14, 2023	litvack frank	acquired	28,839	1.39	20,748	-
Aug 14, 2023	litvack frank	sold (taxes)	-28,846	6.61	-4,364	-

Which funds bought or sold CAPR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Point72 Asia (Singapore) Pte. Ltd.	new	-	160,774	160,774	0.04%
May 15, 2024	STATE STREET CORP	added	36.96	375,811	792,556	-%
May 15, 2024	WELLINGTON MANAGEMENT GROUP LLP	new	-	541,564	541,564	-%
May 15, 2024	MORGAN STANLEY	added	134	524,549	757,743	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-7.27	33,363	149,394	-%
May 15, 2024	Federation des caisses Desjardins du Quebec	new	-	26,236	26,236	-%
May 15, 2024	New Millennium Group LLC	sold off	-100	-289	-	-%
May 15, 2024	OCCUDO QUANTITATIVE STRATEGIES LP	new	-	176,927	176,927	0.03%
May 15, 2024	Woodline Partners LP	reduced	-98.63	-4,363,050	84,610	-%
May 15, 2024	Walleye Capital LLC	new	-	323,516	323,516	-%

Are Funds Buying or Selling CAPR?

Are funds buying CAPR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CAPR

No. of Funds

Unveiling Capricor Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 07, 2024	highbridge capital management llc	9.1%	2,789,699	SC 13G
Oct 17, 2023	nippon shinyaku co ltd	6.97%	2,145,922	SC 13G
Aug 03, 2021	feinberg larry n	0.00%	0	SC 13G/A
Feb 08, 2021	feinberg larry n	9.78%	2e+06	SC 13G
Dec 27, 2019	armistice capital, llc	4.99%	243,184	SC 13G

Recent SEC filings of Capricor Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 15, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
Apr 29, 2024	8-K	Current Report
Apr 25, 2024	4	Insider Trading
Apr 24, 2024	4	Insider Trading
Apr 01, 2024	DEF 14A	DEF 14A
Apr 01, 2024	ARS	ARS
Mar 20, 2024	PRE 14A	PRE 14A

Peers (Alternatives to Capricor Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Capricor Therapeutics Inc News

Latest updates

Capricor Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-59.4%	4,907	12,088	6,186	3,917	2,987	960	1,592	-	-	204	41.00	58.00	17.00	50.00	186	222	142	410	231	648	219
Operating Expenses	13.5%	15,173	13,369	13,050	11,665	11,171	9,026	8,069	6,380	4,315	5,287	5,202	4,238	3,931	3,538	2,293	1,705	1,770	2,476	2,788	3,954	4,391
S&GA Expenses	-100.0%	-	3,429	3,021	2,847	3,510	2,794	2,565	2,116	1,801	1,790	1,906	1,493	1,302	1,610	1,138	877	912	832	976	1,105	1,259
R&D Expenses	11.7%	11,100	9,940	10,029	8,817	7,662	6,232	5,504	4,273	2,500	3,500	3,296	2,745	2,629	1,927	1,155	829	858	1,644	1,811	2,858	3,132
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-1185.2%	-9,794	-762	-6,390	-7,366	-7,768	-7,720	-6,371	-6,190	-3,931	-4,748	-5,151	-4,177	-3,910	-3,484	-2,084	-1,469	-1,606	-2,046	-2,519	-3,259	-4,136
Net Income Margin	-1.4%	-0.90*	-0.89*	-2.08*	-3.09*	-5.23*	-11.37*	-15.31*	-81.76*	-59.49*	-56.29*	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	84.6%	-1,877	-12,152	-9,064	-9,553	3,862	-7,596	-6,243	-5,996	-3,806	-4,836	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-15.8%	49.00	59.00	37.00	46.00	54.00	50.00	54.00	58.00	65.00	41.00	43.00	40.00	44.00	35.00	36.00	37.00	14.00	11.00	8.00	7.00	9.00
Current Assets	-18.6%	41.00	51.00	30.00	39.00	47.00	43.00	48.00	53.00	60.00	36.00	41.00	39.00	43.00	34.00	35.00	37.00	14.00	11.00	7.00	7.00	8.00
Cash Equivalents	-57.7%	6.00	15.00	9.00	10.00	11.00	10.00	8.00	16.00	58.00	35.00	41.00	38.00	42.00	33.00	35.00	36.00	13.00	4.00	7.00	6.00	7.00
Net PPE	6.0%	6.00	6.00	5.00	5.00	5.00	5.00	4.00	3.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	1.00	1.00
Liabilities	-14.2%	31.00	36.00	39.00	43.00	48.00	38.00	39.00	39.00	40.00	10.00	6.00	7.00	7.00	6.00	6.00	5.00	5.00	4.00	4.00	5.00	5.00
Current Liabilities	-15.6%	26.00	31.00	33.00	35.00	37.00	24.00	23.00	20.00	14.00	4.00	3.00	3.00	4.00	3.00	2.00	2.00	1.00	1.00	1.00	2.00	2.00
Shareholder's Equity	-18.4%	18.00	23.00	-	3.00	6.00	12.00	15.00	19.00	25.00	31.00	37.00	33.00	36.00	28.00	30.00	32.00	10.00	7.00	4.00	2.00	4.00
Retained Earnings	-6.1%	-169	-159	-158	-152	-144	-137	-129	-122	-115	-108	-101	-97.94	-93.19	-88.04	-83.86	-79.95	-76.47	-74.38	-72.91	-71.30	-69.26
Additional Paid-In Capital	3.1%	187	182	157	155	151	149	145	142	140	139	139	131	130	116	114	112	86.00	81.00	76.00	74.00	73.00
Accumulated Depreciation	14.5%	3.00	2.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	1.5%	32.00	31.00	26.00	26.00	25.00	25.00	24.00	24.00	24.00	24.00	23.00	23.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	120	-	-	-	83.00	-	-	-	115	-	-	-	87.00	-	-	-	9.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	89.1%	-1,268	-11,594	-8,794	-9,417	4,210	-6,902	-5,685	-6,542	24,047	-5,627	-3,337	-4,514	-3,329	-3,842	-2,977	-2,016	-1,218	-1,785	-1,651	-1,777	-1,607
Share Based Compensation	75.4%	3,265	1,862	1,717	1,619	2,195	1,148	1,087	1,158	1,065	780	720	712	753	474	487	704	288	128	225	124	223
Cashflow From Investing	-62.1%	-9,502	-5,862	7,721	6,461	-3,211	5,142	-4,176	-35,412	-625	-368	-468	-322	-36.91	-288	-152	-107	5,987	-5,986	-	-	2,985
Cashflow From Financing	-90.1%	2,290	23,167	221	2,188	4.00	2,950	1,882	15.00	27.00	42.00	6,567	1,035	12,580	1,496	2,177	25,159	4,550	4,611	2,588	546	1,433
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	193*	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CAPR Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
REVENUE
Revenue	$ 4,906,877	$ 2,986,696
TOTAL REVENUE	4,906,877	2,986,696
OPERATING EXPENSES
Research and development	11,101,013	7,661,519
General and administrative	4,071,766	3,509,885
TOTAL OPERATING EXPENSES	15,172,779	11,171,404
LOSS FROM OPERATIONS	(10,265,902)	(8,184,708)
OTHER INCOME (EXPENSE)
Investment income	471,829	416,442
TOTAL OTHER INCOME (EXPENSE)	471,829	416,442
NET LOSS	(9,794,073)	(7,768,266)
OTHER COMPREHENSIVE INCOME (LOSS)
Net unrealized gain (loss) on marketable securities	71,888	(10,258)
COMPREHENSIVE LOSS	$ (9,722,185)	$ (7,778,524)
Net loss per share, basic (in dollars per share)	$ (0.31)	$ (0.31)
Net loss per share, diluted (in dollars per share)	$ (0.31)	$ (0.31)
Weighted-average number of shares of common stock outstanding basic (in shares)	31,354,629	25,247,354
Weighted-average number of shares of common stock outstanding diluted (in shares)	31,354,629	25,247,354

CAPR Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS
Cash and cash equivalents	$ 6,214,647	$ 14,694,857
Marketable securities	33,702,431	24,792,846
Receivables	369,000	10,371,993
Prepaid expenses and other current assets	1,125,844	995,776
TOTAL CURRENT ASSETS	41,411,922	50,855,472
PROPERTY AND EQUIPMENT, net	5,893,552	5,560,641
OTHER ASSETS
Lease right-of-use assets, net	1,845,246	2,050,042
Other assets	293,722	268,172
TOTAL ASSETS	49,444,442	58,734,327
CURRENT LIABILITIES
Accounts payable and accrued expenses	6,248,657	6,250,241
Lease liabilities, current	771,506	749,112
Deferred revenue, current	19,363,589	24,270,465
TOTAL CURRENT LIABILITIES	26,383,752	31,269,818
LONG-TERM LIABILITIES
CIRM liability	3,376,259	3,376,259
Lease liabilities, net of current	1,249,493	1,486,783
TOTAL LONG-TERM LIABILITIES	4,625,752	4,863,042
TOTAL LIABILITIES	31,009,504	36,132,860
COMMITMENTS AND CONTINGENCIES (NOTE 6)
STOCKHOLDERS' EQUITY
Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding
Common stock, $0.001 par value, 50,000,000 shares authorized, 31,600,183 and 31,148,320 shares issued and outstanding, respectively	31,600	31,148
Additional paid-in capital	187,257,063	181,701,859
Accumulated other comprehensive income	307,701	235,813
Accumulated deficit	(169,161,426)	(159,367,353)
TOTAL STOCKHOLDERS' EQUITY	18,434,938	22,601,467
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 49,444,442	$ 58,734,327

About Capricor Therapeutics Inc

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

CEO	Dr. Linda MarbÃƒÂ¡n Ph.D.
WEBSITE	capricor.com
INDUSTRY	Biotechnology
EMPLOYEES	74

Capricor Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Capricor Therapeutics Inc? What does CAPR stand for in stocks?

CAPR is the stock ticker symbol of Capricor Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Capricor Therapeutics Inc (CAPR)?

As of Thu May 16 2024, market cap of Capricor Therapeutics Inc is 179.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CAPR stock?

You can check CAPR's fair value in chart for subscribers.

What is the fair value of CAPR stock?

You can check CAPR's fair value in chart for subscribers. The fair value of Capricor Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Capricor Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CAPR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Capricor Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CAPR is over valued or under valued. Whether Capricor Therapeutics Inc is cheap or expensive depends on the assumptions which impact Capricor Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CAPR.

What is Capricor Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, CAPR's PE ratio (Price to Earnings) is -7.38 and Price to Sales (PS) ratio is 6.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CAPR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Capricor Therapeutics Inc's stock?

In the past 10 years, Capricor Therapeutics Inc has provided -0.203 (multiply by 100 for percentage) rate of return.